Appclon Registers Domestic Patent for Bispecific Antibody 'AM105'... Begins Primate Testing
Patent Registered for CD137-Binding Affibody Sequence; Applications Filed in Seven Countries Including the US and Europe
Toxicity Testing Initiated at Partner's Request; Pursuing Global Technology Transfer
Appclon announced on August 14 that it has completed domestic patent registration for a core technology applied to its next-generation bispecific antibody cancer immunotherapy, "AM105."
Previously, AM105-related patents were filed in seven countries and regions, including the United States, Europe, China, Japan, India, Russia, and Brazil. The latest patent concerns the Affibody sequence that specifically binds to the extracellular domain of the receptor "CD137," which is responsible for activating the immune response of T cells. The patent covers the amino acid sequences of eight CD137-binding Affibody variants, as well as related protein complexes and anti-cancer compositions, thereby defining the scope of their proprietary rights.
AM105 is a pipeline candidate developed using Appclon's bispecific antibody platform "AffiMab." It targets both EGFR, a major tumor marker in colorectal and lung cancer, and CD137, which is involved in T cell activation.
AM105 binds to cancer cells via EGFR and then activates CD137, thereby triggering an anti-cancer immune response at the tumor site. The company aims to focus immune activation at tumor sites through this approach, reducing side effects associated with systemic immune activation.
Appclon explained that, in preclinical studies, AM105 demonstrated anticancer potential in situations where conventional EGFR-targeted therapies such as cetuximab and panitumumab were ineffective or where resistance emerged after treatment with EGFR inhibitors such as gefitinib and erlotinib.
Currently, at the request of a partner company showing interest in AM105, Appclon has initiated primate toxicity testing. Based on the results, the company plans to pursue global technology transfer and joint development.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A company representative stated, "With this patent registration, we have secured rights to the CD137-binding Affibody sequence, the core of AffiMab," and added, "Alongside AM105 development, we will also pursue platform expansion to target various tumor markers."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.